Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS Evaluation of MN-166(Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Pa ...
A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to ...
A Clinical Trial To Evaluate The Efficacy And Safety Of Mn-166 (Ibudilast) In Subjects With Amyotrophic Lateral Sclerosis(Lou Gehrig's disease) A Clinical Trial To Evaluate The Efficacy And Safety Of Mn-166(Ibudilast) In Subjects With Amyotroph ...
A PHASE 2B/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12 MONTH CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MN-166 (IBUDILAST) FOLLOWED BY AN OPEN-LABEL EXTENSION IN SUBJECTS WITH AMYOTROPHIC LATERAL SCLEROSIS - COMBAT-ALS A PHASE 2B/3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 12 MONTH CLINICAL TRIAL TO ...
A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS) A Biomarker Study to Evaluate MN-166(Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS) ...
A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS) A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166(Ibudilast) in Subjects With Amyotrophi ...
Amyotrophic Lateral Sclerosis
Drug: ibudilast
MediciNova
Massachusetts General Hospital;South Shore Neurologic Associates
Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)
A Single-center, Randomized, Double-blind, Placebo-controlled, 6-month Trial Followed by an Open-label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of Ibudilast (MN-166) in Subjects With (ALS) A Single-center, Randomized, Double-blind, Placebo-controlled, 6-month Trial Followed by an Open-lab ...